$NVO $LLY
Dr. Reddy’s is preparing to enter the GLP-1 market in India.
The company aims to launch generic semaglutide for obesity in the coming months.
Key points
• Collaborating with two leading Indian companies for branded distribution
• Planning to launch higher-dose versions
#stocks#Investing